What is Abelacimab?

In 2020 we posted news about a new DOAC, osocimab, an early and ongoing effort to develop a monoclonal antibody that neutralizes FXI and FXIa. Click here for a press release from Anthos Therapeutics (formerly Blackstone Life Sciences) describing results from the AZALEA-TIMI 71 study that was discontinued early due to an overwhelming reduction in the composite of major and clinically relevant non-major bleeding in patients taking abelacimab, an alternative anti-FXIa monoclonal antibody, compared with patients taking rivaroxaban. Anti-FXI and anti-FXIa research, based on our understanding of the minimal bleeding symptoms in FXI-deficient subjects, hopes to protect from VTE frequency equivalent to the DOACs apixaban, rivaroxaban, and dabigatran while reducing the risk of bleeding.